SEC Form 4 · accession 0001209191-18-061051
Cidara Therapeutics, Inc. · CDTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James E. Levine
Officer — Chief Financial Officer
Period of report
Dec 3, 2018
Accepted (ET)
Dec 4, 2018 · 6:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001610618
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.62 | Dec 3, 2018 | A | 175,000 | A | — | Dec 2, 2028 | Common Stock | 175,000 | 175,000 | D |
Explanation of responses
- F125% of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of December 3, 2018; 1/48th of the shares subject to the option shall vest monthly thereafter, such that all shares will be vested on December 3, 2022.